Privately-held US biotech NeoImmuneTech has joined the club of companies testing their therapeutic alongside Merck & Co’s (NYSE: MRK) blockbuster immuno-oncology drug Keytruda (pembrolizumab).
NeoImmune’s Hyleukin-7 (NT-I7) will enter a trial alongside the Merck anti-PD1 therapy in relapsed/refractory (R/R) advanced solid tumors.
The goal of the Phase Ib/IIa study is to establish a recommended dosing regimen and explore the preliminary anti-tumor activity of the combination in patients with both checkpoint inhibitor (CPI)-treated and CPI-naïve R/R tumors.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze